ARIAD Pharmaceuticals, Inc.
ARIAD is engaged in the discovery and development of breakthrough medicines to treat cancer by regulating cell signaling with small molecules. The company's lead product candidate, AP23573, is in clinical development for the treatment of solid tumors and hematologic malignancies. ARIAD’s preclinical programs include an oncogenic kinase inhibitor program to treat solid tumors, certain forms of leukemia and to block the spread of cancer, and a bone-targeted mTOR inhibitor program to treat cancer that has spread to bone and to treat primary bone cancers, such as osteogenic sarcomas. AP23573 can also be used in drug-delivery stents to reduce reblockage of arteries following angioplasty and stenting. ARIAD also has an exclusive license to pioneering technology and patents related to the discovery, development and use of drugs to regulate NF-kB cell-signaling activity, which may be useful in treating certain medically important disorders, including inflammation, sepsis, cancer and osteoporosis.Back to list